Oxford's new corona vaccine is reported to be '82.4% in two doses'
Regarding the efficacy of the new coronavirus vaccine ' ChAdOx 1 nCoV-2019 ' jointly developed by Oxford University with AstraZeneca in the period of 22 to 90 days after inoculation, '76%' for single dose and '76%' for double dose Reported that the result was '82.4%'.
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine :: SSRN
Oxford coronavirus vaccine shows sustained protection of 76% during the 3-month interval until the second dose | University of Oxford
ChAdOx 1 nCoV-2019 is a vaccine jointly developed by Oxford University and AstraZeneca with the aim of 'permanently providing the new coronavirus vaccine to low- and middle-income countries for non-commercial purposes.' Phase III trials of ChAdOx 1 nCoV-2019 are being conducted in the United Kingdom, Brazil, South Africa, etc., and in November 2020, there was an interim report that 'the efficacy rate was 70.4%'.
Report that the new corona vaccine developed by Oxford University and AstraZeneca showed high efficacy --GIGAZINE
Phase III trials are still ongoing as of February 3, 2021, but Oxford University reported that a single dose was '76%' more effective than it was in November 2020. The effective rate of 76% is for the period from '22 days' to 90 days for antibody formation, and Oxford University said, 'In this period, the protective function of the antibody was hardly attenuated. It also reports.
Furthermore, as a result of a study on multiple doses, it was found that the 'dose interval' is important when multiple doses are administered. Oxford University said that the efficacy of the second dose less than 6 weeks after the first dose was '54.9%', while the second dose after 12 weeks or more was '82.4%'. It explains that it showed high effectiveness.
Based on these results, the Joint Committee on Vaccination and Vaccination (JCVI), which advises the UK health authorities, is making policy recommendations regarding ChAdOx 1 nCoV-2019 'should be administered at 12-week intervals'. He is looking for the best approach for the full-scale deployment of ChAdOx 1 nCoV-2019.
In addition, Oxford University has been accused of medical ethics, saying that it did not notify the subjects even though it administered the wrong amount in the clinical trial of ChAdOx 1 nCoV-2019.
Oxford University not informing clinical trial participants of vaccine dose error | Reuters
in Science, Posted by darkhorse_log